CONCERT: Better QoL but not survival with cabazitaxel in metastatic HER2– breast cancerJune 7, 2021Breast CancerASCO Breast CancerMetastatic Breast Cancer
ASCO 2021: Breast cancer sessions not to missJune 4, 2021Breast CancerMetastatic Breast CancerASCO Breast Cancer
IL-6 levels predict distant breast cancer recurrenceJune 4, 2021Metastatic Breast CancerBreast CancerASCO Breast Cancer
Trastuzumab deruxtecan-related lung disease in MBC patients can occur anytime in first yearJune 2, 2021Metastatic Breast CancerBreast Cancer
Endocrine therapy benefits in premenopausal breast cancer differ by molecular riskMay 26, 2021Breast CancerMetastatic Breast Cancer
New targeted treatments are major advances for HER2-positive breast cancerMay 21, 2021Breast CancerMetastatic Breast Cancer
GELATO trial: Chemoimmunotherapy may help in metastatic invasive lobular breast cancerMay 19, 2021Metastatic Breast CancerBreast Cancer
FDA panel votes against 2 cancer indications but backs 4 of 6April 30, 2021ImmunotherapyBreast CancerGenitourinary CancerGastrointestinal CancerPatient & Survivor CareMetastatic Breast Cancer
FDA panel backs atezolizumab for mTNBC – at least for nowApril 28, 2021Breast CancerMetastatic Breast Cancer
Cell-free DNA improves response prediction in breast cancerApril 21, 2021Breast CancerMetastatic Breast Cancer
PET predicts response to endocrine therapy in ER+ breast cancerFebruary 19, 2021Breast CancerMetastatic Breast Cancer
Obesity ‘clearly’ not tied to worse survival in metastatic breast cancerFebruary 1, 2021Breast CancerMetastatic Breast Cancer
Entinostat doesn’t overcome endocrine resistance in advanced breast cancerJanuary 12, 2021Breast CancerMetastatic Breast Cancer
After 48 years, NCI aims to track breast cancer recurrencesJanuary 8, 2021Breast CancerMetastatic Breast Cancer
Margetuximab approved for HER2-positive metastatic breast cancerDecember 18, 2020Breast CancerMetastatic Breast Cancer
